文献速递妇科

乐伐替尼联合帕博利珠单抗治疗子宫内膜癌的评估:一项真实世界多机构实践模式、疗效与耐受性回顾

Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability.
PubMed 文献 · Gynecol Oncol · 2025-08-14

这项多机构观察性研究纳入188例晚期/复发性子宫内膜癌患者,真实世界中乐伐替尼起始剂量以14 mg为主(47.3%),帕博利珠单抗200 mg每3周方案占94.1%;不同起始剂量间≥3级不良事件率、缓解率、无进展生存期和总生存期均无统计学差异,白人与黑人患者间缓解率和生存期亦相似。

要点

  • 真实世界中乐伐替尼起始剂量以14 mg(47.3%)和20 mg(19.7%)为主,中位剂量强度为14 mg。
  • 不同乐伐替尼起始剂量间≥3级不良事件率(p=0.31)和缓解率(p=0.50)均无统计学差异。
  • 白人与黑人患者的缓解率(p=0.24)、无进展生存期(p=0.66)和总生存期(p=0.22)相似。

核心结论

  • 真实世界分析中,乐伐替尼主要起始剂量为14 mg,帕博利珠单抗为200 mg。
  • 以不同剂量起始似乎不损害缓解率或生存期,且未出现新的严重不良事件。

研究设计与样本

  • 由全国多学科联盟开展观察性研究,纳入2019年至2022年接受乐伐替尼/帕博利珠单抗治疗的晚期/复发性子宫内膜癌患者188例,来自14家机构。
  • 治疗决策基于医生建议。

主要发现

  • 组织学亚型为子宫内膜样33%、浆液性41%、混合型9.6%、癌肉瘤10.1%、透明细胞2.1%。
  • 85.6%为pMMR,5.3%为dMMR。
  • 乐伐替尼起始剂量20 mg占19.7%、18 mg占14.9%、14 mg占47.3%、10 mg占18.1%,中位剂量强度为14 mg。
  • 帕博利珠单抗200 mg每3周方案占94.1%。
  • 与乐伐替尼相关的≥3级不良事件率在各起始剂量间相似:20 mg为13.5%、18 mg为17.9%、14 mg为7.9%、10 mg为17.6%(p=0.31)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: KEYNOTE-775 defined lenvatinib/pembrolizumab as the new standard-of-care for patients with proficient mismatch repair (pMMR) recurrent EC. However, the regimen required dose reductions in 66.5 % of participants and the generalizability of these results was uncertain. We conducted an observational study to determine the prescribing patterns, outcomes and side effects in a real-world setting. METHODS: A national multidisciplinary consortium was utilized to study treatment patterns of patients with advanced/recurrent EC treated with lenvatinib/pembrolizumab from 2019 through 2022. Treatment decisions were based on the physician's recommendation. RESULTS: 188 patients across 14 institutions were included. Histologic subtypes were 33 % endometrioid, 41 % serous, 9.6 % mixed, 10.1 % carcinosarcoma, and 2.1 % clear cell. 85.6 % were pMMR and 5.3 % were dMMR. Lenvatinib starting dose was 20 mg in 19.7 %, 18 mg in 14.9 %, 14 mg in 47.3 %, and 10 mg in 18.1 %. Median dose intensity of lenvatinib was 14 mg. Pembrolizumab dosing was 200 mg Q3W in 94.1 %. Grade ≥ 3 adverse events (AE) rates related to lenvatinib were similar across starting doses: 20 mg (13.5 %), 18 mg (17.9 %), 14 mg (7.9 %), 10 mg (17.6 %) (p = 0.31). Response rates in relation to lenvatinib starting dose were 20 mg (27 %), 18 mg (35.7 %), 14 mg (39.3 %), 10 mg (44.1 %) (p = 0.50). In relation to lenvatinib starting dose, PFS, OS and duration of therapy were not statistically different. Response rates (p = 0.24), PFS (p = 0.66) & OS (p = 0.22) were similar in White and Black patients. CONCLUSIONS: In a real-world analysis, the predominant starting dose was 14 mg lenvatinib and 200 mg pembrolizumab. Starting at varying doses does not appear to compromise response rates or survival and no new severe adverse events emerged.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Corr BR, Thomas SM, Haight PJ, et al. Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability. Gynecol Oncol. 2025. PMID: 40816031. doi:10.1016/j.ygyno.2025.08.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。